| J0717 | Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 146,800 | $1 | $587.2K |
| J0129 | Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 12,680 | $30 | $430.9K |
| J1602 | Injection, golimumab, 1 mg, for intravenous use | 26,050 | $10 | $286.6K |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | 2,510 | $30 | $65.3K |
| J0897 | Injection, denosumab, 1 mg | 3,540 | $20 | $63.7K |
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 560 | $90 | $51.8K |
| 96413 | Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These… | 460 | $100 | $46.2K |
| 96401 | The provider administers nonhormonal, antineoplastic chemotherapy drugs subcutaneously or intramuscularly to the patient. | 780 | $60 | $43.9K |
| 99215 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the… | 160 | $130 | $21.2K |
| 99205 | The provider sees a new patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the provider… | 40 | $160 | $6.1K |